Abstract Number: 0909 • ACR Convergence 2024
Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics
Background/Purpose: Multiple factors can predispose individuals to development of SLE, including the presence of African American ancestry, lupus-associated autoantibodies (ANAs), or some clinical manifestations of…Abstract Number: 2245 • ACR Convergence 2024
Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs
Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…Abstract Number: 0113 • ACR Convergence 2024
Plasma Proteomics Analysis Identifies Thromboinflammatory Signature Associated with Clinical Antiphospholipid Syndrome: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thromboembolic and obstetric morbidity arising via a model of immunothrombosis. Patients may present with thrombotic (tAPS),…Abstract Number: 0961 • ACR Convergence 2024
Multi-omics Study of Systemic Sclerosis Immunoglobulins G Effects on Endothelial Cells: A Distinct Profile in Anti-Topoisomerase I Positive Patients
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease characterized by autoimmunity, fibrosis and vasculopathy. Antinuclear antibodies (ANA) are strong diagnostic and prognosis biomarkers…Abstract Number: 2263 • ACR Convergence 2024
The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…Abstract Number: 0127 • ACR Convergence 2024
Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China
Background/Purpose: Antiphospholipid syndrome (APS) is a complex disease characterized by the presence of anti-phospholipid antibodies (aPLs). Its significant clinical heterogeneity brings clinical and therapeutical challenges.…Abstract Number: 1383 • ACR Convergence 2024
Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the proteomics profiles of patients who were inadequate responders to Etanercept (ETN-IRs) and develop an…Abstract Number: 2333 • ACR Convergence 2024
Unveiling New Molecular Signatures in Psoriatic Arthritis Using Comprehensive Proteomic Analysis of Peripheral Mononuclear Cells
Background/Purpose: Diagnosing psoriatic arthritis (PsA) is challenging, underscoring the importance of discovering novel biomarkers through proteomics for early and accurate detection. Molecular clustering can elucidate…Abstract Number: 0151 • ACR Convergence 2024
Immunoproteomic Profiling of Antibodies in Autoimmune Diseases
Background/Purpose: Prior research has investigated a limited range of candidate markers within individual autoimmune diseases. This study aimed to identify specific and common autoantibodies and…Abstract Number: 1463 • ACR Convergence 2024
Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…Abstract Number: 2379 • ACR Convergence 2024
Causal Proteomics-Assisted Machine Learning Model Enhances Flare Risk Prediction in Systemic Lupus Erythematosus
Background/Purpose: Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease marked by unpredictable flares. However, no flare risk prediction model has been developed for Asian…Abstract Number: 0116 • ACR Convergence 2023
Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by a hypercoagulable state, leading to arterial, venous, or microvascular thrombosis and accelerated atherosclerosis. Timely diagnosis…Abstract Number: 1765 • ACR Convergence 2023
Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives
Background/Purpose: Cigarette smoking (CS) is a major environmental risk factor for the development of Rheumatoid Arthritis (RA), and is associated with the development of RA…Abstract Number: 0427 • ACR Convergence 2023
Molecular Characterization of Biologic and Targeted Synthetic DMARDs Effects Through Ex- vivo Studies in Rheumatoid Arthritis Immune Cells
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, a significant proportion of patients (10-30%) fail to respond to current medications, including biologics. A better characterization…Abstract Number: 1780 • ACR Convergence 2023
Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
Background/Purpose: Axial spondyloarthritis (AxSpA) is a frequent inflammatory disease with a significant impact on a patient's quality of life. Therefore, early diagnosis and recognition of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »